New
HealthMore in Health →
Genentech Halts Muscle Drug Trials, Raising Obesity Study Doubts
Roche's Genentech has abandoned late-stage development of a muscle-building drug in two rare genetic diseases, casting uncertainty on a parallel obesity trial testing the same compound.
DE
DT Editorial AI··via endpoints.news